Cargando…
The integrative epigenomic-transcriptomic landscape of ER positive breast cancer
BACKGROUND: While recent integrative analyses of copy number and gene expression data in breast cancer have revealed a complex molecular landscape with multiple subtypes and many oncogenic/tumour suppressor driver events, much less is known about the role of DNA methylation in shaping breast cancer...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673726/ https://www.ncbi.nlm.nih.gov/pubmed/26664652 http://dx.doi.org/10.1186/s13148-015-0159-0 |
_version_ | 1782404794742210560 |
---|---|
author | Gao, Yang Jones, Allison Fasching, Peter A. Ruebner, Matthias Beckmann, Matthias W. Widschwendter, Martin Teschendorff, Andrew E. |
author_facet | Gao, Yang Jones, Allison Fasching, Peter A. Ruebner, Matthias Beckmann, Matthias W. Widschwendter, Martin Teschendorff, Andrew E. |
author_sort | Gao, Yang |
collection | PubMed |
description | BACKGROUND: While recent integrative analyses of copy number and gene expression data in breast cancer have revealed a complex molecular landscape with multiple subtypes and many oncogenic/tumour suppressor driver events, much less is known about the role of DNA methylation in shaping breast cancer taxonomy and defining driver events. RESULTS: Here, we applied a powerful integrative network algorithm to matched DNA methylation and RNA-Seq data for 724 estrogen receptor (ER)-positive (ER+) breast cancers and 111 normal adjacent tissue specimens from The Cancer Genome Atlas (TCGA) project, in order to identify putative epigenetic driver events and to explore the resulting molecular taxonomy. This revealed the existence of nine functionally deregulated epigenetic hotspots encompassing a total of 146 genes, which we were able to validate in independent data sets encompassing over 1000 ER+ breast cancers. Integrative clustering of the matched messenger RNA (mRNA) and DNA methylation data over these genes resulted in only two clusters, which correlated very strongly with the luminal-A and luminal B subtypes. Overall, luminal-A and luminal-B breast cancers shared the same epigenetically deregulated hotspots but with luminal-B cancers exhibiting increased aberrant DNA methylation patterns relative to normal tissue. We show that increased levels of DNA methylation and mRNA expression deviation from the normal state define a marker of poor prognosis. Our data further implicates epigenetic silencing of WNT signalling antagonists and bone morphogenetic proteins (BMP) as key events underlying both luminal subtypes but specially of luminal-B breast cancer. Finally, we show that DNA methylation changes within the identified epigenetic interactome hotspots do not exhibit mutually exclusive patterns within the same cancer sample, instead exhibiting coordinated changes within the sample. CONCLUSIONS: Our results indicate that the integrative DNA methylation and transcriptomic landscape of ER+ breast cancer is surprisingly homogeneous, defining two main subtypes which strongly correlate with luminal-A/B subtype status. In particular, we identify WNT and BMP signalling as key epigenetically deregulated tumour suppressor pathways in luminal ER+ breast cancer, with increased deregulation seen in luminal-B breast cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-015-0159-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4673726 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46737262015-12-10 The integrative epigenomic-transcriptomic landscape of ER positive breast cancer Gao, Yang Jones, Allison Fasching, Peter A. Ruebner, Matthias Beckmann, Matthias W. Widschwendter, Martin Teschendorff, Andrew E. Clin Epigenetics Research BACKGROUND: While recent integrative analyses of copy number and gene expression data in breast cancer have revealed a complex molecular landscape with multiple subtypes and many oncogenic/tumour suppressor driver events, much less is known about the role of DNA methylation in shaping breast cancer taxonomy and defining driver events. RESULTS: Here, we applied a powerful integrative network algorithm to matched DNA methylation and RNA-Seq data for 724 estrogen receptor (ER)-positive (ER+) breast cancers and 111 normal adjacent tissue specimens from The Cancer Genome Atlas (TCGA) project, in order to identify putative epigenetic driver events and to explore the resulting molecular taxonomy. This revealed the existence of nine functionally deregulated epigenetic hotspots encompassing a total of 146 genes, which we were able to validate in independent data sets encompassing over 1000 ER+ breast cancers. Integrative clustering of the matched messenger RNA (mRNA) and DNA methylation data over these genes resulted in only two clusters, which correlated very strongly with the luminal-A and luminal B subtypes. Overall, luminal-A and luminal-B breast cancers shared the same epigenetically deregulated hotspots but with luminal-B cancers exhibiting increased aberrant DNA methylation patterns relative to normal tissue. We show that increased levels of DNA methylation and mRNA expression deviation from the normal state define a marker of poor prognosis. Our data further implicates epigenetic silencing of WNT signalling antagonists and bone morphogenetic proteins (BMP) as key events underlying both luminal subtypes but specially of luminal-B breast cancer. Finally, we show that DNA methylation changes within the identified epigenetic interactome hotspots do not exhibit mutually exclusive patterns within the same cancer sample, instead exhibiting coordinated changes within the sample. CONCLUSIONS: Our results indicate that the integrative DNA methylation and transcriptomic landscape of ER+ breast cancer is surprisingly homogeneous, defining two main subtypes which strongly correlate with luminal-A/B subtype status. In particular, we identify WNT and BMP signalling as key epigenetically deregulated tumour suppressor pathways in luminal ER+ breast cancer, with increased deregulation seen in luminal-B breast cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-015-0159-0) contains supplementary material, which is available to authorized users. BioMed Central 2015-12-09 /pmc/articles/PMC4673726/ /pubmed/26664652 http://dx.doi.org/10.1186/s13148-015-0159-0 Text en © Gao et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Gao, Yang Jones, Allison Fasching, Peter A. Ruebner, Matthias Beckmann, Matthias W. Widschwendter, Martin Teschendorff, Andrew E. The integrative epigenomic-transcriptomic landscape of ER positive breast cancer |
title | The integrative epigenomic-transcriptomic landscape of ER positive breast cancer |
title_full | The integrative epigenomic-transcriptomic landscape of ER positive breast cancer |
title_fullStr | The integrative epigenomic-transcriptomic landscape of ER positive breast cancer |
title_full_unstemmed | The integrative epigenomic-transcriptomic landscape of ER positive breast cancer |
title_short | The integrative epigenomic-transcriptomic landscape of ER positive breast cancer |
title_sort | integrative epigenomic-transcriptomic landscape of er positive breast cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673726/ https://www.ncbi.nlm.nih.gov/pubmed/26664652 http://dx.doi.org/10.1186/s13148-015-0159-0 |
work_keys_str_mv | AT gaoyang theintegrativeepigenomictranscriptomiclandscapeoferpositivebreastcancer AT jonesallison theintegrativeepigenomictranscriptomiclandscapeoferpositivebreastcancer AT faschingpetera theintegrativeepigenomictranscriptomiclandscapeoferpositivebreastcancer AT ruebnermatthias theintegrativeepigenomictranscriptomiclandscapeoferpositivebreastcancer AT beckmannmatthiasw theintegrativeepigenomictranscriptomiclandscapeoferpositivebreastcancer AT widschwendtermartin theintegrativeepigenomictranscriptomiclandscapeoferpositivebreastcancer AT teschendorffandrewe theintegrativeepigenomictranscriptomiclandscapeoferpositivebreastcancer AT gaoyang integrativeepigenomictranscriptomiclandscapeoferpositivebreastcancer AT jonesallison integrativeepigenomictranscriptomiclandscapeoferpositivebreastcancer AT faschingpetera integrativeepigenomictranscriptomiclandscapeoferpositivebreastcancer AT ruebnermatthias integrativeepigenomictranscriptomiclandscapeoferpositivebreastcancer AT beckmannmatthiasw integrativeepigenomictranscriptomiclandscapeoferpositivebreastcancer AT widschwendtermartin integrativeepigenomictranscriptomiclandscapeoferpositivebreastcancer AT teschendorffandrewe integrativeepigenomictranscriptomiclandscapeoferpositivebreastcancer |